These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39367145)

  • 21. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.
    Shiota M; Fujimoto N; Itsumi M; Takeuchi A; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
    Ann Oncol; 2017 Mar; 28(3):569-575. PubMed ID: 27993795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
    Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
    Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
    Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
    Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Jiménez N; Garcia de Herreros M; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; García-Esteve S; Rodríguez-Carunchio L; Trias I; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domènech M; Figols M; Carles J; Suárez C; Herrero Rivera D; González-Billalabeitia E; Cívico C; Sala-González N; Ruiz de Porras V; Ribal MJ; Prat A; Mellado B
    Eur Urol Oncol; 2024 Aug; 7(4):954-964. PubMed ID: 38429210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study.
    Lee YHA; Chan JSK; Hui JMH; Tang P; Liu K; Dee EC; Ng K; Tse G; Ng CF
    Cancer Med; 2024 Jan; 13(1):e6826. PubMed ID: 38140773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
    Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
    Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.
    Pan T; Lin SC; Lee YC; Yu G; Song JH; Pan J; Titus M; Satcher RL; Panaretakis T; Logothetis C; Yu-Lee LY; Lin SH
    Oncogene; 2021 Jul; 40(27):4592-4603. PubMed ID: 34127814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
    Dwina Y; Zaid LSM; Saraswati M; Rachmadi L; Kekalih A; Rahadiani N; Louisa M; Agustina H; Mochtar CA; Hamid ARAH
    Prostate; 2024 Jun; 84(8):738-746. PubMed ID: 38528654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.].
    Valencia-Guadalajara VJ; Martínez-Cayuelas L; Sarrió-Sanz P; Sánchez-Caballero L; Polo-Hernández R; Chillón-Sempere FS; Galán-Llopis JA; Garcés-Valverde M; Tenza-Tenza JA; Costa-Martínez A; García Serrado-Paumard D; Escudero-Fontana E; Tello-Royloa C; Verdú-Verdú LP; Bravo-López DF; Pérez Seoane-Ballester H; Pacheco-Bru JJ; Ortiz-Gorraiz MÁ
    Arch Esp Urol; 2020 Jul; 73(6):499-508. PubMed ID: 32633245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
    Nishizawa K; Hattahara K; Onishi H; Yoshida T
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
    Hamilton RJ; Ding K; Crook JM; O'Callaghan CJ; Higano CS; Dearnaley DP; Horwitz EM; Goldenberg SL; Gospodarowicz MK; Klotz L
    Eur Urol; 2021 Apr; 79(4):446-452. PubMed ID: 33390282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
    Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.